28th September 2015, Nekta Nutrition, a subsidiary of New Zealand based Nekta Healthcare, today announces the launch of their UK based business operation. A new e-commerce portal, www.nektanutrition.com will sell a range of natural nutrition and healthcare supplements, with a focus on products backed by New Zealand-based scientific research.
The website will launch with the brand PROTEC ProbioticsTM, which brings patented BLIS oral live cultures directly to the UK for the first time. These live cultures, BLIS K12TM and BLIS M18TM, are particular strains of the naturally occurring Streptococcus salivarius, developed through 20+ years of academic research by Professor John Tagg from the University of Otago, New Zealand.
The basis of Tagg’s research was the identification of powerful strains of Streptococcus salivarius in children who exhibited a resistance to throat infections including strep throat. BLIS K12TM and BLIS M18TM are the resulting patented products from the academic studies and trials. Blis Technologies Ltd was formed to produce the live cultures commercially and have existing distribution channels in the North America, Australasia and Asia. A number of subsequent academic global studies are also available for reference.
Nekta Nutrition’s launch products dailyPROTECTM and dentalPROTECTM contain strong doses of BLIS K12TM and BLIS M18TM. “With the global market for probiotics showing considerable annual growth, the timing is perfect to launch these products.” says Gabrielle Lovering, founder and director of the UK business, “The patented BLIS cultures are the only microbiota developed for oral health so we are excited to offer the PROTEC brand to UK consumers for the first time”.
www.nektanutrition.com will initially service the UK and plan to expand this into Ireland and mainland Europe alongside further development of the PROTEC Probiotics range and additional product streams.
Nekta Nutrition UK Ltd is based in The West End, London. Founder and director is Michael Thornton, a sales and operations professional. Nekta Healthcare Ltd is headquartered in Auckland, New Zealand and its major shareholder is an investor in a number of healthcare products and brands including BLIS Technologies Ltd.
Tagg et al. 2003: (New Zealand) Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol. 2003 Sep;52(Pt 9):829-33.
Power et al. 2008: (New Zealand) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17.
Kazor et al. 2003: (USA) Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 2003 Feb;41(2):558-563
Di Pierro et al. 2013: (Italy) Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43.
30+ more global studies listed here http://blis.co.nz/research-studies
To learn more about the product, website, or to book an interview, contact Gabrielle Lovering at email@example.com, or visit the website at www.nektanutrition.com